A calm reading of 25 years of Selank research from Moscow's molecular-genetics institutes

The short version

Selank is a small synthetic peptide — seven amino acids — developed in Russia and studied as a non-sedating way to reduce anxiety. In research, it appears to work mainly two ways: it gently amplifies the brain's own calming chemical system (GABA), and it slows down enzymes that break apart the body's natural stress-easing molecules (enkephalins). Animal studies and a limited set of Russian clinical trials report steadier, less anxious states without the sedation or dependence that benzodiazepine drugs can cause. Almost all of this data comes from Russian research centers, with limited independent Western replication, so the evidence is interesting but not settled. Selank is not approved by the FDA. What people who use it for research actually report — including real downsides — is on the effects page.

What is Selank?

Selank is a synthetic heptapeptide with the amino acid sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in collaboration with the V.V. Zakusov Research Institute of Pharmacology in Moscow, and has been studied continuously since the late 1980s.

The molecule's starting point is tuftsin — a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G that acts as an endogenous immunomodulator. Selank extends tuftsin by adding a Pro-Gly-Pro tripeptide sequence at the C-terminus. That three-residue addition was deliberate: it significantly improves metabolic stability by resisting the tissue peptidases that rapidly degrade native tuftsin, giving Selank a longer window of biological activity in vivo ^[18].

The molecular formula is C33H57N11O9, with a molecular weight of 751.9 Da. The CAS number is 129954-34-3. In Russia, Selank is registered under the trade name Selanc as a prescription nasal spray for generalized anxiety disorder (GAD) and neurasthenia — the only regulatory approval it holds anywhere in the world. In the United States and European Union, Selank has no approved indication and is classified as a research chemical.

The compound is sometimes described as a 'nootropic anxiolytic' — a shorthand for its dual profile in the preclinical literature: reducing anxiety-like behavior in rodent stress models while simultaneously improving markers of learning and memory consolidation. Whether that dual profile holds at the doses and routes studied in human trials is one of the more interesting questions in the existing data.

Five mechanisms the research identifies

Selank's pharmacological profile is notably multi-target, which distinguishes it mechanistically from benzodiazepines despite a partially overlapping receptor interaction.

GABA-A positive allosteric modulation. Radioligand binding studies in rat brain membrane preparations show that Selank enhances [3H]GABA binding at GABA-A receptor subtypes in a concentration-dependent, subtype-selective manner. Its binding site is distinct from — though capable of partially interfering with — the classic benzodiazepine site ^[1]. The practical implication: Selank amplifies the effect of GABA that is already present rather than substituting for it.

Enkephalinase inhibition. Selank inhibited enkephalin-degrading enzymes (enkephalinases) in human plasma with an IC50 of approximately 15 micromolar, outperforming the reference inhibitors bacitracin and puromycin ^[2]. Enkephalins are endogenous opioid pentapeptides; by slowing their degradation, Selank prolongs their activity at mu- and delta-opioid receptors. Studies in patients with generalized anxiety disorder found that the rate of enkephalin degradation in plasma correlated with anxiety severity — a finding that gives this mechanism direct clinical relevance ^[2].

BDNF upregulation. Intranasal Selank administration in Wistar rats produced measurable changes in brain-derived neurotrophic factor (BDNF) mRNA and protein levels in hippocampal tissue ^[3]. BDNF supports neuronal survival, synaptic plasticity, and memory consolidation. A separate study found that Selank (0.3 mg/kg, 7 days) prevented the elevation of BDNF in the hippocampus and frontal cortex that accompanies ethanol withdrawal — while simultaneously protecting against alcohol-induced memory impairment ^[4].

Serotonergic modulation. Selank (300 microg/kg) acutely elevated serotonin (5-HT) turnover in the hypothalamus and caudal brainstem for 30 minutes to 2 hours post-injection in Wistar rats. Administering Selank during the consolidation phase of a conditioned task enhanced 30-day memory retention, and the nootropic effect appeared to be linked to this serotonergic mechanism ^[14].

Cytokine suppression. Under a 20-day chronic social stress protocol in rats, Selank (100 microg/kg/day, intraperitoneal) significantly reduced the stress-elevated pro-inflammatory cytokines IL-1beta, IL-6, TNF-alpha, and TGF-beta1 toward control-group baseline levels, while restoring IL-4 ^[10]. A parallel human cell-culture study found that Selank at 10(-7) M completely suppressed IL-6 gene expression in peripheral blood lymphocytes from patients with depressive anxiety disorders ^[17].

What the human clinical data shows

The clinical evidence for Selank is narrower than the preclinical record, and it comes entirely from Russian research centers — a limitation the research community has noted consistently.

The most cited human study is a 62-patient randomized controlled trial comparing intranasal Selank against medazepam (an oral benzodiazepine) in patients diagnosed with GAD and neurasthenia ^[6]. On the Hamilton Anxiety Rating Scale (HARS) and Zung Self-Rating Anxiety Scale, both drugs produced equivalent anxiolytic effects. Selank additionally demonstrated antiasthenic (anti-fatigue) and mild psychostimulant effects that medazepam did not. Selank-treated patients also showed increased tau(1/2) of leu-enkephalin, consistent with the in vitro enkephalinase inhibition data.

A smaller 20-patient GAD study using intranasal Selank at 2700 microg/day revealed two distinct response patterns ^[7]. Forty percent of participants were 'rapid responders' — their full symptom cluster resolved abruptly within 1-3 days, and their HARS scores fell from a mean of 20.3 to 7.0 (p<0.01). The remaining 60% were conventional responders, reaching a similar endpoint (HARS from 16.1 to 6.2) by day 14 (p<0.01). Rapid responders showed greater baseline EEG beta-rhythm reactivity to a single test dose of 900 microg — a potential predictor of response speed.

A third human study examined immunomodulatory effects of Selank in patients with anxiety-asthenic disorders (including depression, GAD, and neurasthenia), finding evidence of Th1/Th2 cytokine balance shifts after a 14-day treatment course ^[17].

All three studies are single-center, conducted at Russian institutes, with sample sizes that would be considered preliminary by current standards for Western regulatory submissions. No large independent Phase III trials have been published in the English-language literature.

What the research record does not yet show

Reading a research record carefully means being as precise about what it does not establish as about what it does.

Selank's published human pharmacokinetic data is essentially absent. No peer-reviewed study in the public literature reports Cmax, Tmax, plasma half-life, or bioavailability in human subjects for the nasal spray formulation. The improved metabolic stability relative to tuftsin is established in vitro and inferred from in vivo behavioral data, but a clean human PK profile has not been published.

Long-term safety data — beyond the 14-day human trial window and the 20-day rat chronic-stress studies — does not exist in the publicly available literature. The absence of published tolerance or withdrawal data in rodents at research doses is often cited as a contrast to benzodiazepines, and the available data supports that framing; but the absence of long-term data means the question has not been rigorously tested rather than having been answered in the negative.

The strain-dependent effects in mice are a genuine complication for extrapolation. Anxiolytic and nootropic effects in the preclinical literature were observed predominantly in BALB/c mice, not in C57BL/6 mice ^[12]. Naloxone pretreatment blocked Selank's anxiolytic effect in BALB/c mice but paradoxically enhanced it in C57BL/6 mice ^[13] — a species-level finding that raises real questions about inter-individual variability in humans.

Finally, all clinical evidence originates from two Moscow research institutes. The absence of independent international replication is the single most significant limitation of the existing human evidence base.